This website uses cookies

The University of Liège wishes to use cookies or trackers to store and access your personal data, to perform audience measurement. Some cookies are necessary for the website to function. Cookie policy.

Back
  1. Home
  2. Statistics

Statistics of Initial efficacy and safety results from ENGOT-ov60/GOG-3052/RAMP 201: A phase 2 study of avutometinib (VS-6766) ± defactinib in recurrent low-grade serous ovarian cancer (LGSOC).

Created with Highcharts 9.2.2Number of downloadsChart context menuNumber of downloadsGenerated via ORBi - 30/05/2025
Created with Highcharts 9.2.2Number of downloadsChart context menuNumber of downloads by countryGenerated via ORBi - 30/05/2025
Created with Highcharts 9.2.2Number of viewsChart context menuNumber of viewsGenerated via ORBi - 30/05/2025
Created with Highcharts 9.2.2Number of viewsChart context menuNumber of views by countryGenerated via ORBi - 30/05/2025
Created with Highcharts 9.2.2Chart context menuOrigin of ORBi's visitorsGenerated via ORBi - 30/05/2025
Contact ORBi